Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
Sagimet Biosciences Inc. - Series A (SGMT)
Company Research
Source: GlobeNewswire
SAN MATEO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that analyses of the Phase 2b FASCINATE-2 study showing that denifanstat elicited fibrosis improvement in patients with advanced fibrosis will be presented at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2025, taking place November 7-11, 2025 in Washington, DC. This abstract has been selected as a Poster of Distinction, and the details are as follows: Title:Denifanstat elicited a significant =2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of phase 2b FASCINATE-2 studySession:MASLD/MASH - Therapeutics: New Agents and Approved/Available Agents ("4001-4103")Date:November 10, 2025, 8:00 am - 5:00 pm ETLocatio
Show less
Read more
Impact Snapshot
Event Time:
SGMT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMT alerts
High impacting Sagimet Biosciences Inc. - Series A news events
Weekly update
A roundup of the hottest topics
SGMT
News
- Sagimet Biosciences (NASDAQ:SGMT) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SGMT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Sagimet Biosciences (NASDAQ:SGMT) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SGMT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
- Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare ConferenceGlobeNewswire
- Sagimet Biosciences Advances Denifanstat: Q3 Earnings And Upcoming Catalysts [Seeking Alpha]Seeking Alpha
SGMT
Earnings
- 11/13/25 - Beat
SGMT
Sec Filings
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- 11/14/25 - Form SCHEDULE
- SGMT's page on the SEC website